Diligence memo · auto-generated · as of July 2, 2026
Clovis Oncology, Inc.
Clovis Oncology, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Clovis Oncology, Inc. operates in Pharmaceuticals, based in BOULDER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Clovis Oncology, Inc. has raised $358M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $192M on 2013-11-19.
Most recent recorded round closed around 2013-11-19.
Valuation (modeled)modeled
Provath models Clovis Oncology, Inc. at approximately $6.8B (range $914M–$14.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.18× the median modeled value of Series D+ Pharmaceuticals companies in 2013–2015 (6 peers) — value vs value, same stage and era. Within the normal band (118% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 12.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 9.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Kv Pharmaceutical Co /De/, Opko Health, Inc., Horizon Pharma, Inc., HLS Therapeutics Inc., Biotie Therapies Corp..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.